Abstract
Current guidelines recommend effective on-demand therapy for patients with hereditary angioedema (HAE). We evaluated agreement between Patient Global Impression of Change (PGI-C) and impact on attack resolution or rescue medication use in HAE patients receiving the oral plasma kallikrein (PKa) inhibitor KVD900.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
